Ann: Further Significant Improvement in Rett Syndrome Patients, page-9

I understand SH concerns , in some cases a Biotech may only be useful for the Discovery and producing solid positive data from the Trialing continuum.

A larger entity with the skills to commercialise the Treatment may be the next stepping stone ,, Big Pharma control the shop front on Medication the interaction between supplier and Retail / Medical Facility is tied up in decades of relationship based market protection.

NTI 164 could well be retailed online from a Non Regulated Market , plenty of cannabinoid products are available legitimately from these sites.

Feel confident that NTI 164 would sail through a TGA application , Management will have a strategy but as many have stated this now is required to be expressed to the wider market.

The discipline of Science is a far cry from Business Management and many science based individuals do not rate marketing or market interaction " Its so good it will sell itself? there will be a queue forming for this treatment" the chasm between Lab and Pharmacy shelf is huge ,, so it may be time to pass the baton to the next team ,,,,

From the current positively resounding data , I personally see significant Value here ,,, Now its time for management to convert that into SH Value ,, IMHO this stock should be circa 14/15c NZT